There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.
Keyphrases
- bipolar disorder
- end stage renal disease
- drug administration
- newly diagnosed
- major depressive disorder
- ejection fraction
- chronic kidney disease
- palliative care
- peritoneal dialysis
- prognostic factors
- ultrasound guided
- single cell
- pain management
- risk assessment
- skeletal muscle
- chronic pain
- patient reported outcomes
- climate change
- glycemic control
- replacement therapy